Conformation-X Therapeutics
Conformation-X is pioneering a new class of drugs that activate the immune system to recognize cancer cells as foreign invaders, helping patients mount a natural anti-tumor response. They develop therapeutics targeting the tumor microenvironment of cancer cells, recruiting and amplifying the patient’s immune system to fight cancer. Their pipeline includes biologics and small molecule drugs that target immune checkpoints, aiming to create breakthrough therapies for hard-to-treat cancers.
Industries
Nr. of Employees
small (1-50)
Conformation-X Therapeutics
45 Dan Rd., Ste. 382, Canton, MA 02021 USA
Products
Immuno-oncology therapeutic pipeline (biologics and orally available small molecules)
A preclinical pipeline of first-in-class biologics and orally available small-molecule drug candidates designed to modulate immune checkpoints and the tumor microenvironment to elicit anti-tumor immune responses.
Immuno-oncology therapeutic pipeline (biologics and orally available small molecules)
A preclinical pipeline of first-in-class biologics and orally available small-molecule drug candidates designed to modulate immune checkpoints and the tumor microenvironment to elicit anti-tumor immune responses.
Expertise Areas
- Immuno-oncology drug discovery
- Tumor microenvironment targeting
- Small-molecule therapeutic development
- Biologic therapeutic development
Key Technologies
- Small-molecule medicinal chemistry
- Biologic therapeutic design
- Ex vivo functional assays
- In vivo animal models
News & Updates
Conformation-X Therapeutics announced that it has closed an oversubscribed funding tranche of $3.65M, bringing the total raised since inception to over $13.5M. The company disclosed successful proof-of-concept studies for its HHLA2 and IL18BP programs, marking critical milestones in cancer drug development.
Conformation-X Therapeutics announced that it has closed an oversubscribed funding tranche of $3.65M, bringing the total raised since inception to over $13.5M. The company disclosed successful proof-of-concept studies for its HHLA2 and IL18BP programs, marking critical milestones in cancer drug development.